Claims
- 1. A pharmaceutical composition to inhibit phenylethanolamine N-methyltransferase comprising a pharmaceutical carrier and, in an effective amount to inhibit phenylethanolamine N-methyltransferase, a tetrahydroisoquinoline compound of the formula: ##SPC3##
- in which:
- R.sub.1 and R.sub.2 are hydrogen, chloro, bromo, fluoro, iodo, trifluoromethyl, amino, lower alkyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl or nitro, provided that R.sub.1 and R.sub.2 are not both hydrogen and provided that when one of R.sub.1 and R.sub.2 is amino or lower alkyl, the other is not hydrogen, amino or lower alkyl and
- R.sub.3 and R.sub.4 are hydrogen, methyl or ethyl or a pharmaceutically acceptable, acid addition salt thereof.
- 2. A pharmaceutical composition of claim 1 in which R.sub.1 and R.sub.2 are chloro, bromo, fluoro or iodo, R.sub.1 and R.sub.2 being the same or different; R.sub.3 is hydrogen, methyl or ethyl and R.sub.4 is hydrogen, and R.sub.3 being in the 3-position.
- 3. A pharmaceutical composition of claim 1 in which R.sub.1 and R.sub.2 are hydrogen, chloro, trifluoromethyl, amino, methyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl or nitro provided that R.sub.1 and R.sub.2 are not both hydrogen and provided that when one of R.sub.1 and R.sub.2 is amino, methyl or nitro, the other is not hydrogen, amino, methyl or nitro; and R.sub.3 and R.sub.4 are hydrogen or methyl.
- 4. A pharmaceutical composition of claim 3 in whch R.sub.1 and R.sub.2 are chloro.
- 5. A pharmaceutical composition of claim 1 in which the tetrahydroisoquinoline compound is 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline hydrochloride.
- 6. A pharmaceutical composition of claim 1 wherein the composition is in the form of a tablet or capsule.
- 7. A pharmaceutical composition of claim 1 in which the tetrahydroisoquinoline compound is present in an amount of from about 50 mg. to about 1000 mg.
- 8. A method of inhibiting phenylethanolamine N-methyltransferase which comprises administering to an animal, in amount sufficient to inhibit phenylethanolamine N-methyltransferase, a tetrahydroisoquinoline compound of the formula: ##SPC4##
- in which:
- R.sub.1 and R.sub.2 are hydrogen, chloro, bromo, fluoro, iodo, trifluoromethyl, amino, lower alkyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl or nitro, provided that R.sub.1 and R.sub.2 are not both hydrogen and provided that when one of R.sub.1 and R.sub.2 is amino or lower alkyl, the other is not hydrogen, amino or lower alkyl and
- R.sub.3 and R.sub.4 hydrogen, methyl or ethyl or a pharmaceutically acceptable, acid addition salt thereof.
- 9. A method of claim 8 in which R.sub.1 and R.sub.2 are chloro, bromo, fluoro or iodo, R.sub.1 and R.sub.2 being the same or different; R.sub.3 is hydrogen, methyl or ethyl and R.sub.4 is hydrogen, said R.sub.3 being in the 3-position.
- 10. A method of claim 8 in which R.sub.1 and R.sub.2 are hydrogen, chloro, trifluoromethyl, amino, methyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl or nitro provided that R.sub.1 and R.sub.2 are not both hydrogen and provided that when one of R.sub.1 and R.sub.2 is amino, methyl or nitro, the other is not hydrogen, amino, methyl or nitro; and R.sub.3 and R.sub.4 are hydrogen or methyl.
- 11. A method of claim 10 in which R.sub.1 and R.sub.2 are chloro.
- 12. A method of claim 8 in which the tetrahydroisoquinoline compound is 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline hydrochloride.
- 13. A method of claim 8 in which the tetrahydroisoquinoline compound is administered in a daily dosage of from about 100 mg. to about 2000 mg.
- 14. A method of producing hypotensive activity which comprises administering to an animal, in an amount sufficient to produce hypotensive activity, a tetrahydroisoquinoline compound of the formula: ##SPC5##
- in which:
- R.sub.1 and R.sub.2 are hydrogen, chloro, bromo, fluoro, iodo, trifluoromethyl, amino, lower alkyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl or nitro, provided that R.sub.1 and R.sub.2 are not both hydrogen and provided that when one of R.sub.1 and R.sub.2 is amino or lower alkyl, the other is not hydrogen, amino or lower alkyl and
- R.sub.3 and R.sub.4 are hydrogen, methyl or ethyl or a pharmaceutically acceptable, acid addition salt thereof.
- 15. A method of claim 14 in which the tetrahydroisoquinoline compound is 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline hydrochloride.
- 16. A method of reducing the formation of epinephrine in an animal under stress which comprises administering to said animal, in amount sufficient to reduce the formation of epinephrine, a tetrahydroisoquinoline compound of the formula: ##SPC6##
- in which:
- R.sub.1 and R.sub.2 are hydrogen, chloro, bromo, fluoro, iodo, trifluoromethyl, amino, lower alkyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl or nitro, provided that R.sub.1 and R.sub.2 are not both hydrogen and provided that when one of R.sub.1 and R.sub.2 is amino or lower alkyl, the other is not hydrogen, amino or lower alkyl and
- R.sub.3 and R.sub.4 are hydrogen, methyl or ethyl or a pharmaceutically acceptable, acid addition salt thereof.
Parent Case Info
This application is a continuation-in-part of Ser. No. 440,925 filed Feb. 8, 1974, now U.S. Pat. No. 3,939,164.
US Referenced Citations (6)
Foreign Referenced Citations (2)
Number |
Date |
Country |
866769 |
Jun 1966 |
JA |
943,071 |
Nov 1963 |
UK |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
440925 |
Feb 1974 |
|